Vaxcyte, Inc.

NasdaqGS PCVX

Vaxcyte, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -622.63 M

Vaxcyte, Inc. Free Cash Flow is USD -622.63 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -153.97% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Vaxcyte, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -245.16 M, a -50.82% change year over year.
  • Vaxcyte, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -162.55 M, a -86.92% change year over year.
  • Vaxcyte, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -86.96 M, a -68.36% change year over year.
  • Vaxcyte, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -51.65 M.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
NasdaqGS: PCVX

Vaxcyte, Inc.

CEO Mr. Grant E. Pickering M.B.A.
IPO Date June 12, 2020
Location United States
Headquarters 825 Industrial Road
Employees 254
Sector Health Care
Industries
Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Similar companies

MRUS

Merus N.V.

USD 39.01

-3.56%

LQDA

Liquidia Corporation

USD 11.36

-3.40%

ACLX

Arcellx, Inc.

USD 64.65

-4.02%

LEGN

Legend Biotech Corporation

USD 31.64

-2.65%

SNDX

Syndax Pharmaceuticals, Inc.

USD 12.60

-1.56%

VTYX

Ventyx Biosciences, Inc.

USD 1.94

-0.51%

LRMR

Larimar Therapeutics, Inc.

USD 3.29

-5.46%

IMCR

Immunocore Holdings plc

USD 28.56

-4.90%

AKRO

Akero Therapeutics, Inc.

USD 21.87

-3.36%

APLS

Apellis Pharmaceuticals, Inc.

USD 27.69

-3.15%

VRDN

Viridian Therapeutics, Inc.

USD 16.86

-5.12%

BMRN

BioMarin Pharmaceutical Inc.

USD 63.81

-4.75%

TVTX

Travere Therapeutics, Inc.

USD 17.07

-8.18%

TECH

Bio-Techne Corporation

USD 74.73

-2.21%

NUVL

Nuvalent, Inc.

USD 72.39

0.74%

STRO

Sutro Biopharma, Inc.

USD 1.72

-3.91%

StockViz Staff

January 15, 2025

Any question? Send us an email